What is William Blair’s Estimate for Altimmune Q3 Earnings?

Altimmune, Inc. (NASDAQ:ALT) – Stock analysts at William Blair lifted their Q3 2025 earnings per share estimates for shares of Altimmune in a research note issued on Tuesday, August 12th. William Blair analyst A. Hsieh now forecasts that the company will earn ($0.32) per share for the quarter, up from their prior estimate of ($0.34). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share. William Blair also issued estimates for Altimmune’s Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.19) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.43) EPS and FY2027 earnings at ($1.49) EPS.

A number of other equities research analysts have also recently weighed in on the company. JMP Securities dropped their price target on Altimmune from $25.00 to $15.00 and set a “market outperform” rating on the stock in a research note on Thursday, July 10th. B. Riley decreased their price objective on Altimmune from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday. UBS Group decreased their price objective on Altimmune from $26.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a report on Wednesday. Finally, The Goldman Sachs Group raised Altimmune to a “strong sell” rating in a report on Thursday, July 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Altimmune has a consensus rating of “Moderate Buy” and a consensus target price of $17.40.

Altimmune Stock Down 1.4%

ALT opened at $3.63 on Friday. Altimmune has a 1-year low of $2.90 and a 1-year high of $11.16. The stock’s fifty day simple moving average is $4.75 and its 200 day simple moving average is $5.28. The company has a current ratio of 20.44, a quick ratio of 15.85 and a debt-to-equity ratio of 0.09. The stock has a market cap of $320.38 million, a PE ratio of -3.08 and a beta of -0.01.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.05. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million.

Institutional Trading of Altimmune

Several large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its holdings in shares of Altimmune by 234.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 14,956 shares of the company’s stock worth $58,000 after purchasing an additional 10,490 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Altimmune by 108.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after purchasing an additional 5,253 shares in the last quarter. Brevan Howard Capital Management LP grew its holdings in shares of Altimmune by 204.1% during the 2nd quarter. Brevan Howard Capital Management LP now owns 133,209 shares of the company’s stock worth $516,000 after purchasing an additional 89,405 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Altimmune by 155.2% during the 2nd quarter. Bank of America Corp DE now owns 716,019 shares of the company’s stock worth $2,771,000 after purchasing an additional 435,467 shares in the last quarter. Finally, Raymond James Financial Inc. boosted its stake in Altimmune by 77.1% in the second quarter. Raymond James Financial Inc. now owns 25,969 shares of the company’s stock valued at $100,000 after buying an additional 11,309 shares in the last quarter. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.